Effect of Aspirin for the Gastric Cancer Prevention in Early Gastric Cancer Patients Who Underwent Endoscopic Resection: a Randomized Controlled Trial

ational Cancer Center0 个研究点目标入组 1,700 人开始时间: 待定最近更新: 2020年2月24日

试验速览

暂无简介。

•1. Men and women aged 19-70 who underwent endoscopic resection for early gastric cancer
•2. Final pathological results after endoscopic resection met the absolute or expanded criteria according to the Japanese Gastric Cancer Treatment guideline 2014 (version 4)
•3. Patients who had negative H. pylori status or those who eradicated H. pylori status
•4. Willingness to sign an informed consent form

•1. Pateints who received aspirin for the secondary prevention of cardiovascular diseases or cerebrovascular diseases
•2. Regular aspirin uses (more than 3 times a week) with 2 months before screening visit
•3. Patients who used anticoagulants or antiplatelet drugs for therapeutic purpose
•4. Previous gastrectomy history
•5. Current treatment for serious medical condition which could hinder participation (such as severe heart dysfunction, liver cirrhosis, renal failure, COPD or bronchial asthma, or uncontrolled infection)
•6. High risk patients for bleeding complications (cerebral aneurysm, vascular malformation, esophageal or gastric varices, or hemophilia, etc)
•7. Active peptic ulcer disease (patients who treated peptic ulcer completely could be enrolled)
•8. Diagnosis and active treatment for other organ cancer (except carcinoma in situ, and non-melanoma skin cancer) within 5 years
•9. Non-curative resection of early gastric cancer after endoscopic resection
•10. Aspirin allergy or contraindication of aspirin use
•11. Pregnant or lactating women
•12. Alcoholism, drug abuse
•13. Inadequte patients for study enrollment according to the evaluation of the study physician
•14. Inability to provide an informed consent
•15. Patients who took a 28-day run-in-period medication less than 80%

发起方

ational Cancer Center